Quest PharmaTech Inc. Completes the Enrollment of Patients in Phase I Clinical Study of SL017 Topical Gel for Photodynamic Therapy of Actinic Keratosis
EDMONTON, June 13 /CNW/ - Quest PharmaTech Inc. ("Quest" or the
"Company") Quest is pleased to announce that patient enrollment has been
completed in the Phase I clinical study of SL017 Topical Gel for the
photodynamic therapy of actinic keratosis (AK), with centers in Edmonton and
Montreal.